Sodium nitrite - Hope Pharmaceuticals

Drug Profile

Sodium nitrite - Hope Pharmaceuticals

Latest Information Update: 24 May 2017

Price : $50

At a glance

  • Originator Hope Pharmaceuticals
  • Developer Hope Pharmaceuticals; Johns Hopkins University
  • Class Antidotes; Antihypertensives; Nitrites; Small molecules; Sodium compounds; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Myocardial infarction; Subarachnoid haemorrhage

Most Recent Events

  • 09 May 2017 Hope Pharmaceuticals terminates a phase II trial in Subarachnoid haemorrhage in USA (IV) (NCT02176837)
  • 22 Aug 2016 Sodium nitrite is still in phase II trials for Subarachnoid haemorrhage and Myocardial infarction in USA (IV)
  • 01 Jun 2014 Hope Pharmaceuticals initiates a phase II trial in Subarachnoid haemorrhage in USA (NCT02176837)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top